🔗 Share this article

Given that the United States undertakes unprecedented adjustments to its vaccine schedules, a particular individual has emerged somewhat surprisingly: Høeg, an American of Danish descent sports medicine doctor and public health researcher who first made her name by casting doubt on coronavirus vaccines during the global health crisis and has focused upon alleged fatalities following COVID-19 immunization in her recent tenure at the US Food and Drug Administration (FDA).

Proposed Overhauls to Pediatric Immunization Schedule

Public health authorities were set to announce sweeping revisions to the childhood vaccine schedule in December, synchronizing the US with the Danish vaccine program, sources say – a major change that would place the US out of step with many the international standard with little proof for public health gain. This reveal has been postponed until the coming year.

Rather than the director of the vaccine center, Tracy Beth Høeg is scheduled to speak at the gathering. She was recently named acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to run the office this calendar year.

A New Direction at the Regulatory Body

This interim role may indicate a tighter collaboration between the drug and biologics branches as Dr. Høeg and Prasad consolidate power at the FDA – and it signals a increased emphasis upon rolling back previously authorized immunizations at the FDA.

The new acting director has frequently advocated for halting certain childhood shot schedules in the US to become more similar to the Danish model, a country with nationalized medicine and a number of inhabitants approximately the population of the state of Wisconsin.

In her initial public appearances, she has kept her attention on vaccination policy – typically the domain of Dr. Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to medication approval.

Questions Over Background

Høeg has little discernible track record in drug development, approval processes or administrative roles, which has been standard for previous heads of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a senior adviser to the FDA chief and the vaccine center since March.

“It seems she lacks to have the requisite experience” for leading the drug-regulation department, said Dr. Jonathan Howard. “She lacks experience running a clinical trial. She is not versed in leading a major agency. She has no expertise in pharmaceutical oversight.”

Past commissioners of CBER would “grasp regulatory frameworks and the research of medication creation”, said Dr. Janet Woodcock. “Frankly, she has not acquired the kind of background that prior appointees who led the center have had.”

The drug center has an enormous portfolio at the agency, Woodcock emphasized.

“The public just pays attention on the new drug program, but the off-patent medication office approves thousands of generic drugs. There’s a biosimilars program, non-prescription drug unit and other areas, and all of those have to be looked after,” Dr. Woodcock said. “The area you neglect, that is the part that I always told people is going to come back to haunt you.”

There is also, a significant management element to the job, which oversees more than 5,000 staff members. “It’s a massive management job, if you execute it properly,” the former official added.

Official Statement and Disputed Initiatives

Regarding concerns about Høeg’s fitness for the role and whether this assignment signifies more teamwork among regulatory chiefs on immunizations, a representative stated that the “questions are based on flawed presumptions”.

“This background is consistent with the functions of her role,” the representative said, noting the time Høeg spent counseling the agency head on “pharmaceutical safety and regulatory science, including computerized risk analysis and shot safety tracking”.

In her interim role, Høeg assumes responsibility for the agency head's controversial fast-track approval initiative, a disputed expedited medication authorization process that apparently worried her predecessors. “By what process are these medications being picked for this fast-track system? Who is making the decisions?” Dr. Howard asked. “There is a lot of lack of transparency going on at the FDA right now.”

Broadly speaking, he said, “the Food and Drug Administration seems to be moving towards less stringent regulations of most medications, except for shots.”

Documented History on Immunizations

Regarding vaccines, Høeg has a more documented, if concerning, track record, Howard said. She published a research paper using non-validated crowd-sourced reports to determine the frequency of heart inflammation following COVID-19 immunization. She consulted for the state of Florida chief medical officer Dr. Joseph Ladapo, who reportedly have altered data to suggest Covid vaccines are riskier than they are.

Included in her “policy goals” for the new federal leadership encompassed changing rules for new vaccines and discontinuing “unnecessary” vaccines, she stated after the election on a audio program. At the agency, Høeg has according to sources suggested excluding young men from obtaining Covid vaccinations.

“She’s an complete true believer who begins with her preconceived notions and tailors the evidence to retrofit the data in a extremely misleading, dishonest manner,” Dr. Howard argued.

Taking Control and a “Revenge Tour”

Høeg became part of fellow contrarians, {like|